Efficacy of cefiderocol- versus colistin-containing regimen for treatment of bacteremic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in COVID-19 patients.

ABSTRACT:

Introduction

ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in patients hospitalized in intensive care units (ICU) is an important and challenging complication, including in COVID-19 patients. Considering the poor lung penetration of most antibiotics, including intravenous colistin due to the poor PK/PD at the infection site, the choice of the best antibiotic regimen is still being debated.

Methods

this was a single-center, observational study conducted from March 2020 to August 2022, including all patients hospitalized consecutively with VAP and concomitant bloodstream infection due to CRAB in the COVID-ICU. The main goal of the study was to evaluate risk factors associated with survival or death at 30 days from VAP onset

SUBMITTER: Russo A 

PROVIDER: S-EPMC10121149 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature